A medical device can perform well in a clinical trial and still generate serious complaints after reaching thousands of patients. That apparent contradiction is often where medical device litigation becomes complicated. Lawsuits involving implants and surgical products rarely hinge on one alarming statistic. Lawyers, doctors, regulators, and manufacturers may be looking at entirely different datasets. For injured patients, understanding what those numbers actually measure can matter as much as the numbers themselves. The controversy surrounding the Cartiva toe implant offers a useful example of how quickly the evidence can become difficult to interpret.
Why One Device Can Produce Very Different Failure Rates
Medical device litigation often begins with a deceptively simple question: how frequently did the product fail? Answering it requires defining both “failure” and the group being measured. A clinical study may count revision surgeries among every participant, while an adverse-event database primarily contains reports involving people who already experienced suspected complications.
The Cartiva synthetic cartilage implant illustrates the problem particularly well. It was designed as an alternative to fusion for certain patients with arthritis of the big toe, yet subsequent reports raised concerns involving pain, subsidence, implant removal, and revision procedures.
A law firm handling product-liability and medical-device matters has examined how the available figures describe different aspects of the device’s performance. Baker Legal Team explains 3 rate discrepancies by distinguishing figures derived from clinical follow-up, adverse-event reports, and other descriptions of device failure. The distinction matters because percentages that initially appear contradictory may simply have different denominators.
Clinical Studies Can Answer a Narrower Question
Clinical studies are useful because researchers start with a defined patient population and track outcomes according to an established methodology. If researchers follow 100 implant recipients and six eventually undergo another operation, the revision rate for that particular group would be six percent.
But revision surgery is only one possible outcome. Other patients might experience persistent pain, stiffness, reduced mobility, or additional complications without undergoing another procedure. A low revision rate therefore does not necessarily mean that nearly everyone was symptom-free.
That distinction can become important in a lawsuit. Attorneys and experts may examine what researchers defined as success, how long participants were followed, which complications were recorded, and whether patients were lost during follow-up. One attractive percentage can summarize a specific endpoint while leaving other clinically meaningful experiences outside the calculation.
Adverse-Event Databases Start With a Different Population
Post-market surveillance becomes increasingly important once a device moves beyond controlled studies and into widespread clinical use. Patients, physicians, hospitals, and manufacturers may report suspected problems to regulatory databases.
Those reports can reveal recurring patterns worth investigating. They should not, however, automatically be treated as a representative sample of everyone who received the product.
Someone whose implant performs exactly as expected has little reason to submit an adverse-event report. A database built around suspected problems can consequently contain a strikingly high proportion of removals, revisions, or other serious outcomes.
That does not make the information useless. In litigation, adverse-event reports may help identify repeated complications, timelines, and possible safety signals. The mistake comes when a percentage describing reported problem cases is presented as though it describes every person who received the device.
A Recall Changes the Picture Without Deciding the Case
A medical device recall naturally attracts attention during litigation. It introduces regulatory action into a dispute that may already involve patient complaints, clinical research, and questions about the manufacturer’s warnings.
The significance of a recall still depends on what prompted it. In the Cartiva example, regulatory records identified higher-than-expected occurrence rates involving outcomes including revision, removal, and implant subsidence. Information of that kind can become relevant when plaintiffs are alleging that a product presented risks beyond those they expected.
A recall does not automatically establish legal liability, though. Product recalls and civil lawsuits serve different purposes. A plaintiff may still need to establish issues involving the alleged defect, injury, causation, warnings, and the law governing the particular claim.
That distinction prevents regulatory action from becoming a shortcut around the evidence required in an individual case.
Medical Records Connect Large Datasets to One Patient
Population statistics can help explain why litigation develops, but every claimant arrives with an individual medical history. That is where records become particularly important.
Operative reports can establish which product was implanted and when. Follow-up notes may show whether the patient initially improved before symptoms returned. Imaging can document structural changes, while records from revision surgery may describe what physicians observed after reopening the affected area.
That chronology can also reveal competing explanations. Preexisting conditions, surgical complications, subsequent injuries, or unrelated health problems may need to be considered before symptoms can reasonably be connected to a device.
For this reason, an alarming failure statistic rarely proves an individual claim by itself. Broader evidence provides context; medical records help determine whether the patient’s actual experience fits the pattern being alleged.
The Timing of a Complication Can Reshape the Evidence
Some device problems appear soon after surgery. Others may take months or years to become noticeable as an implant shifts, loosens, wears, degrades, or affects surrounding tissue and bone.
A delayed complication can make the medical history more difficult to reconstruct. Someone who recovered successfully may not immediately connect renewed pain or declining mobility with an implant received years earlier. Physicians may investigate several possible causes before determining whether the device is involved.
Timing can have legal consequences too. Product-liability claims are subject to filing deadlines that differ according to jurisdiction and circumstances. Disputes may arise over when an injury occurred, when its possible cause became reasonably discoverable, and what the patient knew at particular points.
The timeline therefore becomes more than background information. It can help connect symptoms, treatment, device performance, and legal questions into a coherent sequence.
Similar Lawsuits Can Be Coordinated Without Becoming Identical
When many federal lawsuits involve the same medical device and similar allegations, courts can coordinate them through multidistrict litigation, commonly called an MDL.
This process can make large-scale litigation more manageable. Instead of numerous courts repeatedly handling similar disputes over manufacturer documents, expert evidence, depositions, and other common issues, those pretrial matters can be coordinated.
An MDL is not necessarily the same thing as a class action. Medical device plaintiffs can have substantially different experiences. One person may require revision surgery, another may experience persistent pain, and another may develop complications years after implantation. Medical expenses, treatment histories, and alleged damages can also vary considerably.
The structure reflects the nature of these disputes: evidence concerning the product may be shared across many lawsuits, while injury and causation remain highly individual questions.
The Real Legal Question Goes Beyond a Failure Percentage
Medical device lawsuits can appear straightforward from a distance: a product was implanted, something went wrong, and litigation followed. The underlying evidence is usually far less tidy.
Clinical studies, adverse-event reports, recalls, medical imaging, revision findings, and manufacturer records each answer different questions. None should automatically substitute for another. A high percentage among reported problem cases can create the wrong impression if presented as the experience of all recipients. Likewise, a low revision rate can overlook patients who experienced complications without another operation.
Legal disputes may also examine what manufacturers knew about potential risks, when information became available, and how risks were communicated to physicians and patients. Plaintiffs can challenge a product’s design or warnings, while manufacturers can dispute those allegations and offer alternative explanations for particular injuries.
That is why the most useful question is rarely just, “What is the failure rate?” Better questions ask what counted as failure, who was included, how long patients were followed, and whether the same pattern appears in an individual’s records. In medical device litigation, those distinctions can determine whether an impressive-looking statistic actually says what people assume it does.
